These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36293515)

  • 1. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.
    Albarrán V; Rosero DI; Chamorro J; Pozas J; San Román M; Barrill AM; Alía V; Sotoca P; Guerrero P; Calvo JC; Orejana I; Pérez de Aguado P; Gajate P
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma.
    Jain RK; Singh AM; Wang X; Guevara-Patiño JA; Sonpavde G
    Expert Opin Emerg Drugs; 2023 Mar; 28(1):17-26. PubMed ID: 36882977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Innovations in systemic treatment of urothelial carcinoma].
    Thibault C; Gross-Goupil M
    Bull Cancer; 2020 Jun; 107(5S):S6-S16. PubMed ID: 32620209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
    D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates in Urothelial Carcinomas.
    Sarfaty M; Rosenberg JE
    Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.
    Li XF; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(17):3339-3360. PubMed ID: 32900344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
    Faltas B; Goldenberg DM; Ocean AJ; Govindan SV; Wilhelm F; Sharkey RM; Hajdenberg J; Hodes G; Nanus DM; Tagawa ST
    Clin Genitourin Cancer; 2016 Feb; 14(1):e75-9. PubMed ID: 26541586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving systemic management of urothelial cancers.
    Tan WS; Tan MY; Alhalabi O; Campbell MT; Kamat AM; Gao J
    Curr Opin Oncol; 2023 May; 35(3):186-199. PubMed ID: 36966497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
    Alameddine R; Mallea P; Shahab F; Zakharia Y
    Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
    Niegisch G
    Methods Mol Biol; 2023; 2684():293-301. PubMed ID: 37410242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.